Suleyman Emre KARAKURT, Haci Huseyin DERE, Nurcan KUM, Mehmet Ali ÇETİN, Turan TURHAN, Canan TOPCUOĞLU

Serum TWEAK levels in patients with obstructive sleep apnea syndrome

Aim: The purpose of the study is to research the serum TWEAK levels in obstructive sleep apnea syndrome (OSAS) patients.Material and Methods: Eighty-six subjects were admitted in the study, 59 being in the patient group and 27 in the control group. The patient group was further divided into subgroups of severe OSAS and mild-moderate OSAS. TWEAK levels between the groups were statistically compared. In addition, the correlation of sleep-related variables with TWEAK levels was investigated in the patientgroup.Results: TWEAK levels were lower in the patient group than in the control group. When the correlation between TWEAK levels and sleep-related variables are examined, inversely correlation between TWEAK levels and apnea-hypopnea index, the percentage of total sleep time spent with oxygen saturation below 90% and oxygen desaturation index was found.Conclusion: Serum TWEAK levels in OSAS patients and its relation with sleep variables showed for the first time that TWEAK may be a new inflammatory biomarker for OSAS.

PDF

___

1. The Report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667-89.
2. Atan D, Ozcan KM, Ikinciogulları A, et al. The effect of obstructive sleep apnea syndrome and continuous positive airway pressure treatment on voice performance. Sleep Breath 2015;19:777-82.
3. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008;5:136-43.
4. Li W, Yu Z, Jiang C. Association of serum YKL-40 with the presence and severity of obstructive sleep apnea syndrome. Lab Med 2014;45:220-5.
5. de Lima FF, Mazzotti DR, Tufik S, et al. The role inflammatory response genes in obstructive sleep apnea syndrome: a review. Sleep Breath 2016;20:331-8.
6. Sato S, Ogura Y, Tajrishi MM, et al. Elevated levels of TWEAK in skeletal muscle promote visceral obesity, insulin resistance, and metabolic dysfunction. FASEB J 2015;29:988-1002. 7. Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res 2016;64:44- 50.
8. Martínez-Miguel P, Medrano-Andrés D, Griera-Merino M, et al. Tweak up-regulates endothelin-1 system in mouse and human endothelial cells. Cardiovasc Res 2017;113:207-21.
9. Chang WA, Yen MC, Hung JY, et al. Investigation of the role of tumor necrosis factor-like weak inducer of apoptosis in non-small cell lung cancer. Oncol Rep 2018;39:573-81.
10. Bilgic O, Sivrikaya A, Toker A, et al. Serum levels of TWEAK in patients with psoriasis vulgaris. Cytokine 2016;77:10-3.
11. Jordan W, Cohrs S, Degner D, et al. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm 2006;113:239-54.
12. Vassilakopoulos T, Katsaounou P, Karatza MH, et al. Strenuous resistive breathing induces plasma cytokines: role of antioxidants and monocytes. Am J Respir Crit Care Med 2002;166:1572-8.
13. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea subjects. Am J Respir Crit Care Med 2002;165:934-9.
14. Inancli HM, Enoz M. Obstructive sleep apnea syndrome and upper airway inflammation. Recent Pat Inflamm Allergy Drug Discov 2010;4:54-7.
15. Wang X, Xing GH. Serum YKL-40 concentrations are elevated and correlated with disease severity in patients with obstructive sleep apnea syndrome. Scand J Clin Lab Invest 2014;74:74-8.
16.Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol 2012;92:265-79.
17. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7:411-25.
18. Avilés-Jurado FX, Terra X, Gómez D, et al. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer. Eur Arch Otorhinolaryngol 2015;272:1733-41.
19. Méndez-Barbero N, Gutiérrez-Muñoz C, BlázquezSerra R, et al. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges. Cells 2020;9:405.
20. Liu Q, Xiao S, Xia Y. TWEAK/Fn14 Activation Participates in Skin Inflammation. Mediators Inflamm 2017;2017:6746870.
21. Di Martino L, Osme A, Kossak-Gupta S, et al. TWEAK/ Fn14 Is Overexpressed in Crohn's Disease and Mediates Experimental Ileitis by Regulating Critical Innate and Adaptive Immune Pathways. Cell Mol Gastroenterol Hepatol 2019;8:427-46.
22. Grimstad T, Skoie IM, Doerner J, et al. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. Scand J Gastroenterol 2017;52:420-4.
23. Llauradó G, González-Clemente J-M, Maymó-Masip E, et al. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One 2012;7:43919.
24. Maymó-Masip E, Fernández-Veledo S, Garcia España A, et al. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNFα. J Clin Endocrinol Metab 2013;98:1323-33.
25. Lozano-Bartolomé J, Llauradó G, Rodriguez MM, et al. Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation. Int J Obes (Lond) 2016;40:1337-45.
26. Zhang XB, Zen HQ, Lin QC, et al. TST, as a polysomnographic variable, is superior to the apnea-hypopnea index for evaluating intermittent hypoxia in severe obstructive sleep apnea. Eur Arch Otorhinolaryngol 2014;271:2745-50